Articles by Andrew Moreno
A preclinical mouse study showed hemostasis restoration, as well as use for active bleeding and internal bleeding prevention.
A novel complement-targeting agent shows impressive efficacy and safety without immunosuppression of the classical pathway.
Investigation of a HUNT Study cohort found elevated plasma MBL levels to be associated with increased risk for future VTE.
Reactive oxygen species levels decreased and patients with evident bone marrow failure showed hematological response.
A cohort study of extended-phase anticoagulation following acute management was performed in the phase III EINSTEIN Jr trial.
The agent targets abnormal gene expression in order to control the excessive cell proliferation that occurs in PV.
A study has explored the clinical impact of both mutation-based and non-mutation-based p53 dysfunction in MDS.
Preclinical models show significant efficacy in combos against AML cell lines with FLT3, KMT2A, NPM1, and TP53 mutations.
Investigators used two AI-driven tools to analyze multiple myeloma therapies' clinical literature and patent information.
The two specific combinations recently approved by the MHRA in the UK also have a BLA currently under review at the FDA.
The agent produced favorable safety results, had no dose-limiting toxicities, and did not interfere with CAR T-cell therapy.
The study led by Paul George, MD, PhD, also highlights the importance of patient regimen adherence to secure these benefits.
Approval was based on data from phase 3 studies in the ongoing ATLAS clinical development program.
The findings coincide with patient reports of experiencing increased vaso-occlusive episodes during menses.
Adrián Mosquera Orgueira, MD, PhD, spoke of his team's study into machine learning tools for improving risk stratification.
The Clinical Practice Guidance document issued by the EHA, ISTH, EAHAD, and ESO addresses both hemophilia A and B.
Malignant neoplasm-associated hemophagocytic lymphohistiocytosis, COVID-19, and CAR T-cell therapy can each initiate CS.
In a phase 1 trial the product performed favorably in aplastic anemia, myelofibrosis, and hypoplastic myelodysplasia.
The reduced-dose oral regimen also had lower incidence of clinically relevant bleeding complications and mortality rate.
The platform features incubation technology able to replicate cell microenvironments associated with SCD sickling.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.